Delivery Order SPE2DB22D3501-SPE2DB24FVH40

Award Date 4/16/24
Potential Completion Date 4/17/24
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency (DLA) awarded a $1,584.31 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,651,931 units of Atorvastatin 40 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,039.38 Firm Fixed Price delivery order is for 4,567,490,649 units of 10 mg Atorvastatin tablets. The contract has an ultimate completion date of March 7, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a delivery order (contract) awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of 1,000 units of 40 mg Atorvastatin tablets, a cardiovascular medication, at a firm fixed price of $2,847.24. The contract has a completion date of September 26, 2023. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $1,905.06 firm fixed price delivery order is for 4,562,470,723 units of the drug Atorvastatin 40 mg tablets. The contract has an ultimate completion date of October 16, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as a primary vehicle for providing a...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of 4,565,404,327 units of Atorvastatin 20 mg tablets. The contract, valued at $3,596.23, was awarded by the Defense Logistics Agency (DLA) on August 9, 2024, with a completion date of August 12, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type. This award is not designated as a set-aside contract. Amerisourcebergen...
This federal contract award, valued at $1,668.78, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for 4,567,600 units of Atorvastatin 40 mg tablets, a cardiovascular medication. The contract has an ultimate completion date of March 18, 2025 and is a Firm Fixed Price arrangement. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award, SPE2DB20D1004|SPE2DB23FG6S1, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $4,866.19 firm fixed-price delivery order is for the supply of 4,562,331,415 tablets of 40mg Atorvastatin, a generic cardiovascular medication. The contract has an ultimate completion date of September 28, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award is for the delivery of 4,561,450,705 tablets of 80 mg Atorvastatin, a generic cardiovascular medication, to the Defense Logistics Agency (DLA). The $2,184.90 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on July 10, 2023, with a completion date of July 11, 2023. The award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued...
This federal contract award, valued at $1,627.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,562,601 units of Atorvastatin 40 mg tablets, a cardiovascular medication. The contract has an ultimate completion date of October 26, 2023 and is a Firm Fixed Price Delivery Order. No set-aside designation was used for this award. AmerisourceBergen holds a...
This federal contract award, valued at $3,155.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Atorvastatin 40 mg tablets in quantities of 1,000 to support military healthcare programs. This is a delivery order contract with a firm fixed price arrangement. The contract has an ultimate completion date of July 9, 2024 and was awarded on July 8, 2024....
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB24FVH40
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a $1,076.56 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division for the supply of 4,564,299,676 units of 40mg Atorvastatin tablets. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 held by Amerisourcebergen with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation and was awarded on a full and open competition basis, highlighting Amerisourcebergen's competitive position in the federal pharmaceutical supply market.

Generated 7/16/24, 1:07 PM